Open menu

Observing biological nanotransporters

(Nanowerk News) A research team of the Ruhr-Universität Bochum (RUB) was able to describe with atomic detail how molecules are transported through biological membranes. Computer simulations and spectroscopic experiments provided insights into the work of so-called ABC transporters. These proteins play an important role in the drug resistance of tumour cells and bacteria.
The researchers within the groups of Prof Dr Lars Schäfer and Prof Dr Enrica Bordignon, who work together in the Excellence Cluster Ruhr explores Solvation, Resolv in short, report in the Journal of the American Chemical Society ("Atomistic Mechanism of Large-Scale Conformational Transition in a Heterodimeric ABC Exporter").
Hendrik Göddeke, Lars Schäfer und Enrica Bordignon (from the left) in their laboratory
Hendrik Göddeke, Lars Schäfer und Enrica Bordignon (from the left) in their laboratory.
“ABC transporters are fascinating biological nanomachines”, says Lars Schäfer, head of the Molecular Simulation research group. These proteins couple the binding and chemical cleavage of ATP molecules, the chemical energy unit of the cell, with the transport of molecules through biological membranes.

Resistance of tumour cells and bacteria

A particular characteristic of the so-called ABC exporters is that they transport a very wide range of molecules out of the cell: from lipids and peptides to chemotherapeutic agents. “ABC exporters therefore play an important role, including with regard to multi-drug resistance of cancer cells and antibiotic resistance of bacteria”, explains Schäfer.
The research groups of Lars Schäfer and Enrica Bordignon combined detailed computer simulations with spectroscopic experiments to shed light on the functional mechanism of an ABC exporter in atomic detail.

Hope for new therapy approaches

“Our results show how the binding of ATP molecules induces structural changes in the transporter that are ultimately required to carry substrate molecules through the membrane”, explains Hendrik Göddeke, co-author and doctoral researcher in Lars Schäfer’s group. “We conduct basic research”, says Enrica Bordignon, head of the EPR Spectroscopy research group. In the long term, however, these findings could contribute to the development of new therapeutic approaches. “The goal would be to specifically influence or inhibit these processes”, says Bordignon.
Source: Ruhr-Universität-Bochum
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
 
These articles might interest you as well: